Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine vs Lamivudine in Chinese Adults with Chronic Hepatitis B
NCT00131742Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Primary completion
- Jan 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: Reduction in serum HBV DNA levels at 52 weeks. Started Jul 2004; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00131742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131742.